Updated:
Amgen
Amgen (Thousand Oaks) — Robert Bradway's biotech generated $28.2B in 2024 revenue, developing blockbuster biologics Enbrel and Prolia with a global...
Amgen
Amgen was incorporated in 1980 by scientists and venture investors, launching as a startup in Thousand Oaks, California. Robert Bradway, former chief financial officer, became CEO in 2012 and added chairman in 2021 — a tenure that saw Amgen become the world's largest biotech by market capitalization in 2023. The firm invests internally across therapeutic areas including oncology, inflammation, cardiovascular disease, and bone health, with active drug platforms in antibody engineering and gene editing. Revenue comes from marketed products such as Enbrel (autoimmune), Prolia (osteoporosis), Otezla (psoriasis), Repatha (cholesterol), and biosimilars like MVASI. Amgen's pipeline includes Phase 3 candidates in KRAS-mutant cancers and obesity, disclosed in its 2024 annual report. Amgen employs approximately 26,000 people globally, with research facilities in South San Francisco, Cambridge (Massachusetts), and Hong Kong. In 2023 the firm acquired Horizon Therapeutics for $27.8B, gaining access to rare-disease drugs including Tepezza and Krystexxa, a deal completed that October (per the firm, 2023). The company operates an active philanthropy, the Amgen Foundation, which supports science education globally. Unlike pure biotechs that license discovery, Amgen manufactures its own biologics and maintains a vertically integrated model — discovery through commercial-stage sales and distribution. Its capital allocation prioritizes internal drug development, bolt-on acquisitions, and a steady dividend payout, a structure typical of mature pharma rather than high-growth biotechs.
General information
Firm type
other
Year founded
1980
AUM
Undisclosed
Location
Region
North America
Country
US
City
Thousand Oaks
Corporate office
One Amgen Center Drive, Thousand Oaks, CA 91320, United States
Additional offices
Hong Kong · San Francisco
Principals
Robert A. Bradway
Chairman and Chief Executive Officer
David W. Meline
Executive Vice President and Chief Financial Officer
Sector focus
Frequently asked questions
Who leads Amgen's corporate strategy?
Robert Bradway has served as CEO since 2012 and chairman since 2021. Prior to CEO, he was CFO from 2007 to 2010, shaping the firm's financial posture during its expansion into biosimilars (per Amgen's proxy statement, 2024).
What are Amgen's key therapeutic areas?
Amgen focuses on oncology, inflammation, cardiovascular disease, bone health, and rare diseases. Its marketed portfolio includes Enbrel (rheumatoid arthritis), Prolia (osteoporosis), Repatha (cholesterol), and Otezla (psoriasis). Pipeline highlights include obesity and KRAS-mutant cancer candidates (per Amgen's 2024 annual report).
How did the Horizon Therapeutics acquisition change Amgen?
Amgen closed the $27.8B acquisition of Horizon Therapeutics in October 2023, adding rare-disease drugs Tepezza (thyroid eye disease) and Krystexxa (gout). The deal expanded Amgen's rare-disease footprint and brought in Horizon's commercial infrastructure (per the firm, 2023).
Does Amgen have a philanthropy arm?
Yes, the Amgen Foundation is the firm's independent philanthropic organization. It funds science education programs globally, including the Amgen Biotech Experience program for high schools and the Amgen Scholars program for undergraduate research (per the Amgen Foundation website).
What is Amgen's approach to drug manufacturing?
Amgen operates its own biologics manufacturing facilities rather than contracting out, a vertical integration model that covers discovery through commercial production. This reduces dependency on contract manufacturers and provides control over quality and supply chain (per Amgen's investor materials).
What geographies does Amgen operate in?
Amgen's headquarters are in Thousand Oaks, California. Major R&D hubs include South San Francisco, Cambridge (Massachusetts), and Hong Kong. Sales and marketing teams operate globally, with commercial offices in over 55 countries (per Amgen's 2024 10-K filing).
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: